Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment

BMJ Case Rep. 2010 May 6:2010:bcr11.2009.2457. doi: 10.1136/bcr.11.2009.2457.

Abstract

A case of solitary bone metastasis from breast cancer, where MRI assessment of treatment response was inaccurate and whole-body fluorodeoxyglucose ((18)FDG) positron emission tomography with computed tomography (PET-CT) proved more reliable and objective, is presented.

Publication types

  • Case Reports

MeSH terms

  • Aromatase Inhibitors / therapeutic use
  • Bone Density Conservation Agents / therapeutic use
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery
  • Diphosphonates / therapeutic use
  • Disease Progression
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Ibandronic Acid
  • Letrozole
  • Magnetic Resonance Imaging
  • Middle Aged
  • Multimodal Imaging*
  • Nitriles / therapeutic use
  • Positron-Emission Tomography*
  • Radiopharmaceuticals
  • Spinal Neoplasms / diagnostic imaging*
  • Spinal Neoplasms / drug therapy
  • Spinal Neoplasms / secondary*
  • Tomography, X-Ray Computed*
  • Triazoles / therapeutic use

Substances

  • Aromatase Inhibitors
  • Bone Density Conservation Agents
  • Diphosphonates
  • Nitriles
  • Radiopharmaceuticals
  • Triazoles
  • Fluorodeoxyglucose F18
  • Letrozole
  • Ibandronic Acid